Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego
Hematologia · 2015
DOI: 10.5603/hem.2015.0011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematologia, 2015. Verfasst von Krzysztof Jamroziak.
Abstract (Originalsprache)
During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma resulting in significant prolongation of patients’ overall survival. Since 2010 the efficacy and toxicity of chemotherapy regimens including immunomodulatory drugs and proteasome inhibitors have been further optimized based on the results of numerous, large phase 3 randomized clinical trials. Moreover, intensive efforts have been made to identify novel molecular drug targets to individualize treatment and overcome resistance to existing therapies. Currently, the most promising therapeutic strategy is immunotherapy, especially development of monoclonal antibodies against CD38 antigen .
Zitieren
APA
Jamroziak, K. (2015). Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego. Hematologia. https://doi.org/10.5603/hem.2015.0011
Vancouver
Jamroziak K. Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego. Hematologia. 2015. doi:10.5603/hem.2015.0011
BibTeX
@article{Jamroziak2015,
author = {Jamroziak, Krzysztof},
title = {Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego},
journal = {Hematologia},
year = {2015},
doi = {10.5603/hem.2015.0011}
}
EUVIMED